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ABSTRACT
In high-risk patient cohorts, such as patients after solid-organ or allogeneic stem-cell transplantation, or
patients with acute leukaemia, early diagnosis of invasive fungal infections (IFIs) is essential, as delayed
or missing diagnosis of IFI results in increasing rates of mortality. However, diagnosis of most IFIs,
especially of invasive aspergillosis, is difficult because classic tests have low sensitivity and specificity,
and radiology often provides non-specific and transient results. The limited sensitivity and specificity of
conventional assays for the detection of IFI and the growing number of immunocompromised patients
who are at risk for opportunistic fungal infections have led to the development of new assays. These
methods include antigen detection systems, such as ELISAs, and different molecular methods (PCR
assays). Serological tests, such as the detection of the carbohydrate galactomannan, are standardised and
commercially available. However, they still need to be evaluated in large patient cohorts, especially
children. The benefit of antibody detection remains unclear if patients are under immune suppression or
are heavily colonised but not infected. A range of different PCR assays (conventional, nested, real-time)
have been developed, targeting different gene regions (cytochrome P450, heat-shock proteins, 18S, 5.8S,
28S, internal transcribed spacer), including a variety of amplicon detection methods, such as gel
electrophoresis, hybridisation with specific probes, ELISA and restriction fragment length polymor-
phism. These molecular assays provide high potential in terms of sensitivity and specificity, but vary
widely in their feasibility and up to now have not been standardised. Taken together, new non-culture-
based diagnostic assays are appropriate as simple and rapid screening tests with high sensitivities and
quick turnaround times. Thus, they might help to reduce empirical antifungal therapy and might be
valuable tools to allow early initiation and monitoring of pre-emptive antifungal therapy. In this review,
we assess the performance of a variety of non-culture-based tests for the detection of IFI in high-risk
haematological patients, with emphasis on the impact of the assays on different management strategies.
Keywords liposomal amphotericin B, fungal infection, A. fumigatus, review
Clin Microbiol Infect 2008; 14 (Suppl. 4): 37–45
INTRODUCTION
Moulds are ubiquitous inhabitants of the soil.
These species, of which the most clinically rele-
vant is Aspergillus fumigatus, can cause different
diseases in humans [1], including invasive fungal
infections (IFIs). They occur mainly in immuno-
compromised patients, where deficits in host
defence render them susceptible to IFIs. The risk
of IFI is often related to the degree and duration
of neutropenia [2]. Thus, most cases of IFI occur in
patients receiving potent cytotoxic therapies for
haematological malignancies or myeloablative
allogeneic stem-cell transplantation (alloSCT).
However, other groups of patients, such as
patients after solid-organ transplantation and
critically ill patients receiving high-dose cortico-
steroid therapies, are also at risk for IFI. In this
review, we will focus on invasive aspergillosis
(IA), as this infection is still the major cause of
infection-related morbidity and mortality in
almost all cohorts of immunocompromised
patients. The primary localisation of IA is the
lung, where alveolar macrophages constitute the
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first line of defence against airborne spores. From
the lungs, haematogenous dissemination towards
other organs is common. Thereafter, neutrophils
are the dominant host defence against the inva-
sive hyphal form.
Patients after alloSCT have a higher risk of IA
than autologous transplant recipients, as immu-
nosuppressive agents are administered with
greater intensity. Most cases of IA occur in the
early stage after alloSCT, when neutropenia and
mucosal toxicities from conditioning regimens are
the major causes of immune defects. At this stage,
the incidence of IA is strongly related to the
duration and degree of neutropenia. However,
many cases of IA also occur after neutrophil
recovery, such as during immunosuppressive
therapy for graft vs. host disease. Additional risk
factors for IA are T-cell depletion, CD34-selected
stem-cell products, and corticosteroid therapy, as
well as cytomegalovirus and respiratory virus
infections [3]. Besides neutropenia, lymphopenia
is associated with a higher risk of IA, especially
late after alloSCT, as defects in cell-mediated
immunity can persist for several months. In
addition to quantitative T-cell deficiencies, a loss
of T-cell receptor diversity is observed [4].
Morgan et al. recently presented data about the
cumulative incidence of IA after 12 months.
Based on a multicentre surveillance, the incidence
of IA after autologous stem-cell transplantation
was 0.5%, 2.3% after alloSCT from an HLA-
matched related donor, and 3.9% after alloSCT
from an unrelated donor [5]. Taking these num-
bers into account, IA is responsible for a relatively
small number of hospitalisations. However,
patients have long-term hospital stays and mor-
tality rates are over 90%. In 1996, there were over
10 000 patients hospitalised in the USA due to
aspergillosis, resulting in 1970 deaths, 176 300
hospital days and US$ 633 million in costs. The
mean duration of hospitalisation was 17.3 days,
with mean costs of US$ 62 000 [6].
Early diagnosis of IA has been proven to be
mandatory for successful outcome, since it allows
the timely start of antifungal therapy. However,
up to now, diagnosis of IA has remained
difficult, as clinical signs of infection are often
unspecific, and conventional tests, such as blood
cultures, show very low sensitivity.
In general, there are four different diagnostic
procedures that can be used for sensitive detection
of IA [7]: (i) the detection of the cell-wall antigen
galactomannan (GM) by a commercially available
sandwich ELISA; (ii) the detection of the fungal
surrogate marker b-glucan; (iii) the amplification
of Aspergillus DNA by PCR; and (iv) high-resolu-
tion computed tomography (hrCT) of the chest.
ANTIGENAEMIA ASSAYS
The sensitivity of the GM assay varies widely,
depending on the patient cohort, host factors,
nutrition of the patient, and the use of certain
drugs, such as piperacillin–tazobactam [8]. Lom-
bardi et al. described an evaluation of the GM test
in which they enrolled 187 patients with various
kinds of immunosuppression [9]. The results
allowed the exclusion (68.6%) or confirmation
(31.5%: proven or probable IA) of a clinical
diagnosis of IA. The authors concluded that this
assay should be limited to those patients with
clinical symptoms of IA. Sulahian and colleagues
analysed the value of antigen detection in the
diagnosis and prediction of IA in 6209 sera [10].
GM was detected with a sensitivity of 90.6% and
a specificity of 94%. Antigenaemia was positive in
64.6% of the patients, with a mean of )8.4 days
before radiological signs and with a mean of
)6.9 days before clinical symptoms became
apparent. The authors concluded that the pres-
ence of GM has good diagnostic value when the
titre is increasing in two consecutive sera. Salonen
et al. [11] compared the GM assay for the detec-
tion of GM in serum, urine and bronchoalveolar
lavage. In 6 ⁄ 6 patients with proven IA, the
antigen was detectable in serum, but urine was
positive in only two patients. Herbrecht et al. [12]
collected 3294 serum samples from paediatric and
adult haematological patients, including 153 epi-
sodes of IA. The sensitivities of the ELISA were
64.5%, 16.4% and 25.5% in proven, probable and
possible IA, respectively. The overall specificity of
the assay was 94.8%, and the specificity was
lower in children than in adults. As a conse-
quence, Herbrecht et al. proposed a new cut-off
value of 0.700 for non-alloSCT recipients. Sie-
mann et al. [13] investigated the false-positive rate
of the Platelia assay in premature infants. They
found sensitivities of 100% in proven IA, 33% in
probable IA and 50% in possible IA; however, in
5 ⁄ 6 paediatric patients with prolonged intensive
care unit stay, positive GM findings were consid-
ered to be false-positive results. Recently, Maer-
tens et al. presented data obtained from serial
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serum GM analyses performed prospectively in
specimens from neutropenic and alloSCT patients
[14]. The positive and negative predictive values
were 87.5% and 98.4%, respectively. Serial mon-
itoring yielded higher positive and negative
predictive values of 94.4% and 98.8%, respec-
tively. All proven cases of IA (n = 23) could be
detected prior to death [14]. This strategy also
reduced the use of empirical antifungal therapy
from 35% to 7.7% (a 78% reduction) and led to
the early initiation of antifungal therapy in ten
episodes (7.3%). Furthermore, Maertens et al.
explored the performance of the galactomannan
assay when used prospectively [63]. In a follow-
up study [15], the same authors reported that a
reduction of the cut-off OD index for positivity
from 1.5 to 0.5 increased the overall sensitivity by
21% (from 76.3% to 97.4%) but decreased the
overall specificity by 7% (from 97.5% to 90.5%).
Lai et al. collected 304 blood samples from 189
patients at risk of IA during a 1-year period [16].
Diagnostic levels of GM were detected in 80% of
proven and in 77% of probable IA cases. The
overall sensitivity, specificity, and positive and
negative predictive values for this assay, using a
1.5 index cut-off value, were 78.6%, 93.9%,
55.0%, and 97.9%, respectively. With the 0.5
index cut-off value, the sensitivity would increase
to 100% [16]. The GM assay is commercially
available and approved by the FDA, as well as in
Europe, and has been included in the criteria of
the European Organisation for Research and
Treatment of Cancer ⁄Mycoses Study Group (EO-
RTC-MSG) for classification of IA.
An additional antigenaemia ELISA assay
detects the polysaccharide b-1–3-glucan [17].
The components of this assay are purified from
a lysate of the horseshoe crab, Limulus polyphe-
mus [18], including factor G, which triggers the
b-1–3-glucan-sensitive haemolymph clotting
pathway. The detection threshold of the assay
is 10–20 pg ⁄mL serum. The G-test has been used
for the detection of b-1–3-glucan during various
systemic fungal infections in humans and ani-
mals [19–21]. This assay is not able to distin-
guish between fungal species, which was
confirmed by Odabasi et al., who were able to
detect candidosis, fusariosis, trichosporiosis and
aspergillosis with high sensitivity [22]. In
patients after alloSCT, especially in the non-
neutropenic later phase, further studies are
necessary [23]. The assay is approved by the
FDA and has been included in the EORTC ⁄MSG
criteria for possible IA.
CT SCANS
Different radiological tools such as chest radiog-
raphy, CT and magnetic resonance (MR) imaging
are available. The appearance of IA on chest
radiographs is extremely heterogeneous. The
most distinctive appearances are cavitations and
pleural-based, wedge-shaped lesions. In addition,
nodular shadows with and without cavitations
and thin- or thick-walled cavities (especially in
patients with AIDS) are typical signs of IA.
However, pulmonary IA often shows false-nega-
tive chest radiographs. Therefore, high-resolution
CT scans often play an important role in the
detection of IA [24–30]. Early lesions in the lung of
neutropenic patients are small nodules and the
so-called halo sign, corresponding to a central
fungal nodule surrounded by a rim of haemor-
rhage and coagulative necrosis. These nodules
may further cavitate, leading to the air crescent
sign. Both signs are highly distinctive for IA of the
lung, probably representing lung tissue infarcted
with hyphae. The duration of the halo sign is
short, and it demonstrates the value of early
CT. Miaux et al. reviewed imaging data of five
patients with cerebral aspergillosis [31]. They
concluded that lesions are often located in the
basal ganglia and demonstrate intermediate sig-
nal intensity within surrounding high-signal
areas on long-repetition-time MR scans. These
lesions were multiple and more numerous on MR
images than on CT scans.
In another study, high-resolution CT was per-
formed in patients with persistent neutropenic
fever [24]. The authors showed that high-resolu-
tion CT could be used as a prompt to initiate early
antifungal therapy and to improve outcome.
Finally, in one study, sequential high-resolution
CT scans were performed on patients with neu-
tropenia and IA [32]. Despite effective antifungal
therapy, the volume of lesions increased during
the first week of therapy and remained stable
during the second week. Halo signs were regu-
larly diagnosed, but decreased with the increas-
ing frequency of air crescent signs.
In a further study, the diagnostic value of
central hypo-intensity (‘hypodense sign’) in lung
consolidations or nodules in severely immuno-
compromised patients was assessed [33]. These
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authors consider the hypodense sign to be a
supplementary tool in the diagnosis of IA, espe-
cially because of its high specificity.
PCR
Since the first publication on PCR by Saiki et al.
[34] in 1988, several hundred articles on the
application of PCR for the detection of fungal
DNA have been published. However, up to now,
standardisation of procedures and inter-labora-
tory validation have not been optimised.
Which PCR assay is most suitable depends on
the requirement of the method. PCR assays can
be used as: (i) a pan-fungal diagnostic tool only;
(ii) a tool for the early diagnosis of IA, ideally
prior to the onset of clinical symptoms; and (iii) a
tool to monitor pre-emptive antifungal therapy.
Depending on this decision, different technical
aspects have to be considered, including the types
of samples, the extraction of the nucleic acids and
the fungal DNA targets.
Bronchoalveolar lavage fluid [35], cerebrospi-
nal fluid [36], tissue biopsies [37] and continuous
ambulatory peritoneal dialysis fluid [38] have all
been employed. However, obtaining deep tissue
biopsies, CSF and BAL requires invasive proce-
dures that might not be well-suited to critically ill
patients. Also, bronchoalveolar lavage fluid,
although it has the advantage of enabling the
investigation of the primary site of infection (i.e.,
the lungs), is very prone to contamination, as
spores of Aspergillus may be present in the mouth
and upper airways and it may therefore not
discriminate between conidial presence and true
tissue invasion [39]. It is therefore not surprising
that blood is generally considered to be the
preferred specimen [40].
With regard to the best blood fraction to test, a
consensus on the method of choice for nucleic acid
extraction and purification has yet to be reached,
and, of course, the choice of specimen has a great
influence on the extraction methodology. Speci-
mens such as plasma and serum, in which DNA is
free in solution, require more rapid and less
complex protocols for nucleic acid extraction
[41]. The protocols currently employed to break
the fungal cell wall usually rely on enzymic
digestion, such as recombinant lyticase [42], or
mechanical disruption by bead-beating [43].
DNA is generally considered to be the target of
choice, due to its relative stability and ease of
extraction (compared to RNA). The advantage of
selecting a multicopy gene is, obviously, the in-
creased chances of successfully amplifying it to a
detectable level. During recent years, the ribosomal
DNA gene region has been shown to be a prom-
ising target; this is composed of the 18S (1800 bp)
gene, the 5.8S (159 bp) gene and the 28S (3396 bp)
gene. These are separated by, respectively, internal
transcribed spacer (ITS) 1 (361 bp) and ITS 2
(231 bp). Numerous studies have made use of
the different components of the rDNAgene region:
18S [44,45], 28S [46,47], ITS 1 [48] and ITS 2 [49].
MANAGEMENT OF PATIENTS AT
RISK FOR IFI
The four overall management strategies for the
prevention and treatment of patients at high risk
for IFI are: (i) prophylaxis; (ii) empirical antifun-
gal treatment; (iii) pre-emptive antifungal treat-
ment; and (iv) therapy for existing IFI [50].
Besides the use of PCR assays for the diagnosis
of IFI in symptomatic patients, this highly sensi-
tive technology can also be used to pre-emptively
monitor patients at risk of developing IFI, a
strategy successfully used to monitor opportunis-
tic viral infections in alloSCT patients. The aim of
this strategy is to clearly define negative (no
therapy) and positive (initiation or continuation
of therapy, additional screening tests) samples. In
these patients, maximum sensitivities and high
negative predictive values are mandatory to
minimise the risk of false-negative results and
thus over-treatment of a patient.
Once antifungal therapy has been initiated,
quantitative real-time PCR assays can be used to
monitor the success of antifungal therapy strate-
gies by quantification of the fungal load in blood
or tissue specimens. As with monitoring of
antiviral therapies, the reduction of the fungal
load or negative PCR results over time seem to be
favourable, whereas persistence or an increase in
the amount of fungal DNA seems to be correlated
with an unfavourable outcome [51]. Furthermore,
these PCR tests usually precede other signs of
infection, such as radiological signs, by days or
even weeks. However, some authors report false-
negative results during antifungal therapy, even
in patients with progression of disease. The
reason might possibly be an immediate reduction
of the fungal load in the blood, which might
often be only intermittent. Our own group
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demonstrated that the fungal load in whole blood
specimens is very low, often under 10 CFU ⁄mL,
with a maximum of several hundred CFU ⁄mL,
even in patients with proven IA and a fatal
outcome [52]. This underlines the need for PCR
assays with very high sensitivities.
Other important questions are the frequency of
prospective sampling and the number of positive
results of a PCR assay required to initiate anti-
fungal therapy. Most authors suggest analysing at
least two blood samples per week. This is of
special interest because circulation of fungal DNA
in blood is not continuous and, in addition, the
levels are often close to the lower detection limits
of the respective assays [53]. In addition, there is
consensus that at least two consecutive positive
PCR results are required for the initiation of
antifungal therapy [54–58]. The significance of a
single positive PCR result is unclear, especially as
contamination or the transient presence of fungal




Recently, some scientists have started to under-
stand the need to reach a consensus that would
encompass the primer sets, the extraction tech-
nique, and the detection system used. White and
colleagues published the findings of a multicentre
study comparing two primer sets (28S and 18S)
and three platforms (LightCycler (Roche), Taq-
Man (Applied Biosystem) and Rotor-Gene (Corb-
ett Research)) on a panel consisting of eight
negative and eight positive samples (10–5000 con-
idia ⁄mL) [59]. The study revealed that the 28S
assay was more specific than the 18S assay,
particularly since the 18S assay was found to
amplify a portion of the human rDNA gene in the
absence of DNA from A. fumigatus. This interfer-
ence was particularly strong with the LightCycler
and was responsible for a decrease in sensitivity.
Overall, the sensitivity, specificity, negative pre-
dictive value and positive predictive value were
higher with the 28S than the 18S primer set,
regardless of the platform used. The platforms
themselves were found to have a major influence
on the assay, as sensitivity and negative predic-
tive value were 100% on the TaqMan machine,
whereas specificity and positive predictive value
reached 100% using the Rotor-Gene system [59].
Currently, 24 European laboratories are con-
ducting several studies in a Working Group of the
International Society for Human and Animal
Mycology (ISHAM) to arrive at PCR tests that
achieve an agreed standard. In the near future,
this Working Group will also design clinical
studies among high-risk patients using the agreed
standardised assay as a read-out system.
COMBINATION OF DIFFERENT
DETECTION ASSAYS
Several centres have published studies combin-
ing two different assays for the detection of IA, in
most cases the combination of PCR and anti-
genaemia. The benefit of a combination of both
assays is controversial. Two different groups
were able to demonstrate superior sensitivity
using a combination of both assays, as compared
to a single test only [54,60]. Interestingly, Kami
et al. [41] showed that PCR detected the presence
of Aspergillus earlier than did the GM ELISA but,
in a later study, the same group found that
combining the tests reduced sensitivity, possibly
because PCR was more sensitive than the GM
ELISA, whereas the latter test was more specific.
Similarly, combining the GM ELISA with pul-
monary CT scans does not appear to be useful,
since it was recently shown that the detection of
GM occurred significantly later than the detection
of lesions by CT. Univariate and multivariate
analyses revealed no significant association
between GM levels and detection of pulmonary
infiltrates by CT [61].
In contrast to these observations, other authors
were able to show the superior sensitivity of the
galactomannan ELISA compared to CT, such as
Maertens et al., showing the galactomannan to be
detectable 6 days earlier than a positive CT scan
[14]. In addition, Kawazu et al. [56] and Frances-
coni et al. [62] were able to demonstrate that
galactomannan detection is more sensitive than
PCR in humans and rabbits, respectively.
MANAGEMENT STRATEGIES
Early intervention strategies for treatment of IFI
are based on either pre-emptive therapy, which
aims to treat patients with persistent febrile
neutropenia and radiological signs or laboratory
markers or both, or empirical therapy. In the
latter, the initiation of treatment takes place
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without a known source of infection [62]. The
major goal of pre-emptive therapy is early and
targeted therapy with lower toxicities, less drug
interaction and lower costs. For this purpose,
sensitive, reliable and standardised tests are
necessary. The goals of empirical therapy are the
prevention of IFI and the reduction of expensive
fungal screening. However, high costs, toxicities
and drug interactions might be obstacles.
In a recent study, Maertens et al. performed a
GM assay and hrCT for use in a pre-emptive
antifungal therapy setting by analysing 4170
serum samples [14]. In total, 919 positive samples
were found. On the basis of predetermined crite-
ria, 41 ⁄ 136 episodes qualified for empirical anti-
fungal therapy, but only nine were treated
(treatment rate reduced from 35% to 7.7%).
However, ten afebrile episodes were treated
because of a positive GM ELISA. Six of seven
patients with proven IA died. The conclusion from
this study was that a combination of both methods
reduced exposure to expensive and potentially
toxic drugs, but failed to detect non-Aspergillus IFI
as well as IA in patients with relapsing or
persisting neutropenic fever [14].
In a second study, empirical and pre-emptive
therapy were compared in 295 patients with
haematological malignancies, mainly acute mye-
loid leukaemia. Patients were screened twice-
weekly for the presence of GM antigen. The
authors concluded that, although significantly
(p < 0.02) more IFIs were observed with the pre-
emptive strategy (based on clinical symptoms
and GM antigen), the fungal-related mortality of
prolonged neutropenic patients was not different
(Cordonnier C. Empirical versus pre-emptive
antifungal therapy in high-risk febrile neutrope-
nic patients: A prospective randomized study. In:
Abstract of the 48th Annual Meeting of the American
Society of Hematology, Dec 9–12, Orlando, Florida.
2006).
Our own group compared the efficacy and
safety of PCR-based vs. empirical liposomal
amphotericin B treatment after alloSTC [63].
Recipients of allogeneic bone marrow or periph-
eral blood stem-cell transplants were randomised
to receive either PCR-based pre-emptive therapy
(group A; n = 198) or empirical antifungal ther-
apy (group B; n = 211) with liposomal amphoter-
icin B. In group A, therapy was started after one
positive PCR result or after 120 h of febrile
neutropenia refractory to broad-spectrum anti-
bacterial therapy (3 mg ⁄ kg ⁄day, reduced to
1 mg ⁄ kg in stable patients on day 4). In group B,
the same schedule of liposomal amphotericin B
was started after 120 h of febrile neutropenia
refractory to broad-spectrum antibacterial ther-
apy. We concluded that close fungal PCR moni-
toring as performed until day 30 after
transplantation led to a reduction in early mor-
tality and a trend towards a lower rate of early IFI
after alloSCT but that survival was not different at
day 100. Thus, the impact of close PCR monitor-
ing and PCR-based therapy beyond day +30
should be studied in future trials [63].
DETECTION OF FUNGI PREVIOUSLY
CONSIDERED TO BE RARE
One major challenge for modern diagnostic tools
is the species-specific detection of IFI, as the
epidemiology of IFI is changing and rare species
are becoming more prevalent. One example is the
increasing incidence of Aspergillus terreus, a fun-
gus that is intrinsically resistant to amphoteri-
cin B, in some centres (see Richardson and Lass-
Flo¨rl, this supplement).
Besides IFI caused by aspergilli, non-Aspergillus
mould infections are becoming more common.
These include zygomycosis, fusariosis, infections
with Scedosporium spp. and phaeohyphomycosis.
Specific and early detection of these species is
mandatory, as conventional mycology and histo-
pathology assays often fail in species-specific
diagnosis. The incidence of these infections is
steadily increasing; e.g., at some centres, the
frequency of zygomycosis has increased in the
setting of more intensive voriconazole usage
[64,65]. Furthermore, these pathogens are a
challenge to therapy, as early surgical debride-
ment (e.g. in zymomycosis) is necessary, or
intrinsic resistance to some antifungal agents
might be common (e.g. Scedosporium apiospermum
resistance to amphotericin B).
Machouart et al. described specific PCR-based
identification of the main opportunistic Mucorales
by restriction fragment length polymorphism anal-
ysis [66]. They were able to selectively amplify
genomic DNA from moulds belonging to the
genera Absidia, Mucor, Rhizopus, and Rhizomucor.
A subsequent digestion step identified the Muco-
rales at the genus and species levels. This technique
was validated using both fungal cultures and
retrospective analyses of clinical samples.
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Ibrahim et al. established a quantitative real-
time PCR to monitor the burden of Rhizopus
oryzae in brain tissue [67]. They demonstrated by
quantitative PCR that the fungal burden corre-
lated with increasing inocula and progression of
disease and that appropriate antifungal therapy
with caspofungin decreased the brain burden of
R. oryzae when it was given prophylactically (but
not when therapy was started after infection).
FUTURE PERSPECTIVES
Early diagnosis of IFI in high-risk patients is
mandatory, since it has major consequences for
the effectiveness of antifungal therapy, and thus
for prognosis. However, several questions still
remain open and have to be resolved in the near
future. Diagnosis has to be seen in the context of
new antifungal treatment options, such as
lipid amphotericin B formulations, the candins,
the second generation of azoles and immune
augmentation strategies, including granulocyte
transfusions, interferon-c and adoptive transfers
of T-cells or dendritic cells.
The following points should be considered:
• Standardisation of PCR technologies, which
should be achieved by large international
laboratory comparisons as well as clinical trials,
possibly also by including commercial systems.
• Largeprospective studies, inwhich thebenefitof
the different new diagnostic approaches should
be determined. These studies should include
combinations of methods (e.g., antigenaemia
and PCR assays) and should provide informa-
tion about whether these new methods contrib-
ute to reduced mortality and ⁄ or reduced costs.
• Definitions of patients at risk for IFI. Different
patient cohorts, including alloSCT recipients,
solid-organ transplant recipients and patients
with AIDS or chronic granulomatous disease,
have different degrees of risk of acquiring IFI,
and therefore need different diagnostic sur-
veillance strategies.
• The current value of empirical antifungal ther-
apy; its benefitmight be reduceddue to the avail-
ability of effective and safer antifungal therapies
and improved risk stratification methods.
• Standardisation and validation of pre-emptive
antifungal therapy in randomised studies with
well-defined inclusion and exclusion criteria,
such as those for preventing cytomegalovirus
disease after alloSCT.
REFERENCES
1. Stevens D. Aspergillosis. In: Goldman BJ, eds, Cecil
textbook of medicine. Philadelphia, 2000; 1875–1877.
2. Gerson SL, Talbot GH, Hurwitz S et al. Prolonged gran-
ulocytopenia: the major risk factor for invasive pulmonary
aspergillosis in patients with acute leukemia. Ann Intern
Med 1984; 100: 345–351.
3. Marr KA, Carter RA, Boeckh M, Martin P, Corey L.
Invasive aspergillosis in allogeneic stem cell transplant
recipients: changes in epidemiology and risk factors. Blood
2002; 100: 4358–4366.
4. Mackall CL, Gress RE. Pathways of T-cell regeneration in
mice and humans: implications for bone marrow trans-
plantation and immunotherapy. Immunol Rev 1997; 157:
61–72.
5. Morgan J, Wannemuehler KA, Marr KA et al. Incidence of
invasive aspergillosis following hematopoietic stem cell
and solid organ transplantation: interim results of a pro-
spective multicenter surveillance program. Med Mycol
2005; 43 (suppl 1): S49–S58.
6. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergil-
losis-related hospitalizations in the United States. Clin
Infect Dis 2000; 31: 1524–1528.
7. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis
of invasive aspergillosis. Lancet Infect Dis 2005; 5: 609–622.
8. Sulahian A, Touratier S, Ribaud P. False positive test for
aspergillus antigenemia related to concomitant adminis-
tration of piperacillin and tazobactam. N Engl J Med 2003;
349: 2366–2367.
9. Lombardi G, Farina C, Andreoni S et al. Multicenter
evaluation of an enzyme immunoassay (Platelia Asper-
gillus) for the detection of Aspergillus antigen in serum.
Mycopathologia 2002; 155: 129–133.
10. Sulahian A, Boutboul F, Ribaud P et al. Value of antigen
detection using an enzyme immunoassay in the diagnosis
and prediction of invasive aspergillosis in two adult and
pediatric hematology units during a 4-year prospective
study. Cancer 2001; 91: 311–318.
11. Salonen J, Lehtonen OP, Tera¨sja¨rvi MR, Nikoskelainen J.
Aspergillus antigen in serum, urine and bronchoa-
lveolar lavage specimens of neutropenic patients in rela-
tion to clinical outcome. Scand J Infect Dis 2000; 32: 485–490.
12. Herbrecht R, Letscher-Bru V, Oprea C et al. Aspergillus
galactomannan detection in the diagnosis of invasive
aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898–
1906.
13. Siemann M, Koch-Dorfler M, Gaude M. False-positive
results in premature infants with the Platelia Aspergillus
sandwich enzyme-linked immunosorbent assay. Mycoses
1998; 41: 373–377.
14. Maertens J, Theunissen K, Verhoef G et al. Galactomannan
and computed tomography-based preemptive antifungal
therapy in neutropenic patients at high risk for invasive
fungal infection: a prospective feasibility study. Clin Infect
Dis 2005; 41: 1242–1250.
15. Maertens JA, Klont R, Masson C et al. Optimization of the
cutoff value for the Aspergillus double-sandwich enzyme
immunoassay. Clin Infect Dis 2007; 44: 1329–1336.
16. Lai CC, Hsu HL, Lee LN, Hsueh PR. Assessment of Plat-
elia Aspergillus enzyme immunoassay for the diagnosis of
invasive aspergillosis. J Microbiol Immunol Infect 2007; 40:
148–153.
Einsele and Loeffler Contribution of new diagnostic approaches 43
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 4), 37–45
17. Miyazaki T, Kohno S, Mitsutake K et al. Plasma (1–>3)-
beta-D-glucan and fungal antigenemia in patients with
candidemia, aspergillosis, and cryptococcosis. J Clin
Microbiol 1995; 33: 3115–3118.
18. Miyazaki T, Kohno S, Mitsutake K et al. (1–>3)-beta-D-
glucan in culture fluid of fungi activates factor G, a lim-
ulus coagulation factor. J Clin Lab Anal 1995; 9: 334–339.
19. Mitsutake K, Kohno S, Miyazaki T et al. Detection of (1-3)-
beta-D-glucan in a rat model of aspergillosis. J Clin Lab
Anal 1995; 9: 119–122.
20. Obayashi T, Yoshida M, Mori T et al. Plasma (1–>3)-beta-
D-glucan measurement in diagnosis of invasive deep
mycosis and fungal febrile episodes. Lancet 1995; 345:
17–20.
21. Yuasa K, Goto H, Iguchi M, Okamura T, Ieki R. Evaluation
of the diagnostic value of the measurement of (1–>3)-beta-
D-glucan in patients with pulmonary aspergillosis. Respi-
ration 1996; 63: 78–83.
22. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a
diagnostic adjunct for invasive fungal infections: valida-
tion, cutoff development, and performance in patients
with acute myelogenous leukemia and myelodysplastic
syndrome. Clin Infect Dis 2004; 39: 199–205.
23. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Mul-
ticenter clinical evaluation of the (1–>3) beta-D-glucan
assay as an aid to diagnosis of fungal infections in
humans. Clin Infect Dis 2005; 41: 654–659.
24. Caillot D, Casasnovas O, Bernard A et al. Improved man-
agement of invasivepulmonary aspergillosis inneutropenic
patients using early thoracic computed tomographic scan
and surgery. J Clin Oncol 1997; 15: 139–147.
25. Mori M, Galvin JR, Barloon TJ, Gingrich RD, Stanford W.
Fungal pulmonary infections after bone marrow trans-
plantation: evaluation with radiography and CT. Radiology
1991; 178: 721–726.
26. Staples CA, Kang EY, Wright JL, Phillips P, Mu¨ller NL.
Invasive pulmonary aspergillosis in AIDS: radiographic,
CT, and pathologic findings. Radiology 1995; 196: 409–414.
27. Kuhlman JE, Fishman EK, Siegelman SS. Invasive pul-
monary aspergillosis in acute leukemia: characteristic
findings on CT, the CT halo sign, and the role of CT in
early diagnosis. Radiology 1985; 157: 611–614.
28. Blum U, Windfuhr M, Buitrago-Tellez C, Sigmund G,
Herbst EW. Invasive pulmonary aspergillosis. MRI, CT,
and plain radiographic findings and their contribution for
early diagnosis. Chest 1994; 106: 1156–1161.
29. Taccone A, Occhi M, Garaventa A, Manfredini L, Viscoli
C. CT of invasive pulmonary aspergillosis in children with
cancer. Pediatr Radiol 1993; 23: 177–180.
30. Primack SL, Hartman TE, Lee KS, Mu¨ller NL. Pulmonary
nodules and the CT halo sign. Radiology 1994; 190: 513–515.
31. Miaux Y, Ribaud P, Williams M, Guermazi A, Gluckman
E. MR of cerebral aspergillosis in patients who have had
bone marrow transplantation. Am J Neuroradiol 1995; 16:
555–562.
32. Caillot D, Couaillier JF, Bernard A et al. Increasing volume
and changing characteristics of invasive pulmonary
aspergillosis on sequential thoracic computed tomography
scans in patients with neutropenia. J Clin Oncol 2001; 19:
253–259.
33. Horger M, Einsele H, Schumacher U et al. Invasive pul-
monary aspergillosis: frequency and meaning of the
‘hypodense sign’ on unenhanced CT. Br J Radiol 2005; 78:
697–703.
34. Saiki RK, Gelfand DH, Stoffel S et al. Primer-directed
enzymatic amplification of DNA with a thermostable
DNA polymerase. Science 1988; 239: 487–491.
35. Raad I, Hanna H, Huaringa A et al. Diagnosis of invasive
pulmonary aspergillosis using polymerase chain reaction-
based detection of aspergillus in BAL. Chest 2002; 121:
1171–1176.
36. Hummel M, Spiess B, Kentouche K et al. Detection of
Aspergillus DNA in cerebrospinal fluid from patients with
cerebral aspergillosis by a nested PCR assay. J Clin
Microbiol 2006; 44: 3989–3993.
37. Khan ZU, Ahmad S, Mokaddas E et al. Cerebral aspergil-
losis diagnosed by detection of Aspergillus flavus-specific
DNA, galactomannan and (1–>3)-beta-D-glucan in clinical
specimens. J Med Microbiol 2007; 56: 129–132.
38. Scotter JM, Stevens JM, Chambers ST, Lynn KL, Patton
WN. Diagnosis of aspergillus peritonitis in a renal dialysis
patient by PCR and galactomannan detection. J Clin Pathol
2004; 57: 662–664.
39. Tuon FF. A systematic literature review on the diagnosis
of invasive aspergillosis using polymerase chain reaction
(PCR) from bronchoalveolar lavage clinical samples. Rev
Iberoam Micol 2007; 24: 89–94.
40. Rickerts V, Mousset S, Lambrecht E et al. Comparison of
histopathological analysis, culture, and polymerase chain
reaction assays to detect invasive mold infections from
biopsy specimens. Clin Infect Dis 2007; 44: 1078–1083.
41. Kami M, Fukui T, Ogawa S et al. Use of real-time PCR on
blood samples for diagnosis of invasive aspergillosis. Clin
Infect Dis 2001; 33: 1504–1512.
42. Paterson PJ, Seaton S, McLaughlin J, Kibbler CC. Devel-
opment of molecular methods for the identification of
aspergillus and emerging moulds in paraffin wax
embedded tissue sections. Mol Pathol 2003; 56: 368–370.
43. Griffiths LJ, Anyim M, Doffman SR et al. Comparison of
DNA extraction methods for Aspergillus fumigatus using
real-time PCR. J Med Microbiol 2006; 55: 1187–1191.
44. Klingspor L, Jalal S. Molecular detection and identification
of Candida and Aspergillus spp. from clinical samples
using real-time PCR. Clin Microbiol Infect 2006; 12: 745–753.
45. Rickerts V, Just-Nu¨bling G, Konrad F et al. Diagnosis of
invasive aspergillosis and mucormycosis in immunocom-
promised patients by seminested PCR assay of tissue
samples. Eur J Clin Microbiol Infect Dis 2006; 25: 8–13.
46. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA.
The evolution and evaluation of a whole blood polymerase
chain reaction assay for the detection of invasive asper-
gillosis in hematology patients in a routine clinical setting.
Clin Infect Dis 2006; 42: 479–486.
47. Williamson EC, Leeming JP, Palmer HM et al. Diagnosis of
invasive aspergillosis in bone marrow transplant recipi-
ents by polymerase chain reaction. Br J Haematol 2000; 108:
132–139.
48. Lau A, Chen S, Sorrell T et al. Development and clinical
application of a panfungal PCR assay to detect and iden-
tify fungal DNA in tissue specimens. J Clin Microbiol 2007;
45: 380–385.
49. Schabereiter-Gurtner C, Selitsch B, Rotter ML, Hirschl AM,
Willinger B. Development of novel real-time PCR assays
for detection and differentiation of eleven medically
44 Clinical Microbiology and Infection, Volume 14, Supplement 4, May 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 4), 37–45
important Aspergillus and Candida species in clinical
specimens. J Clin Microbiol 2007; 45: 906–914.
50. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of
epidemiology, diagnosis, and treatment of invasive mould
infections in allogeneic hematopoietic stem cell transplant
recipients. Mycopathologia 2006; 162: 1–15.
51. Hebart H, Lo¨ffler J, Reitze H et al. Prospective screening by
a panfungal polymerase chain reaction assay in patients at
risk for fungal infections: implications for the management
of febrile neutropenia. Br J Haematol 2000; 111: 635–640.
52. Lo¨effler J, Kloepfer K, Hebart H et al. Polymerase chain
reaction detection of aspergillus DNA in experimental
models of invasive aspergillosis. J Infect Dis 2002; 185:
1203–1206.
53. O’Sullivan CE, Kasai M, Francesconi A et al. Development
and validation of a quantitative real-time PCR assay using
fluorescence resonance energy transfer technology for
detection of Aspergillus fumigatus in experimental inva-
sive pulmonary aspergillosis. J Clin Microbiol 2003; 41:
5676–5682.
54. Florent M, Katsahian S, Vekhoff A et al. Prospective eval-
uation of a polymerase chain reaction-ELISA targeted to
Aspergillus fumigatus and Aspergillus flavus for the early
diagnosis of invasive aspergillosis in patients with hema-
tological malignancies. J Infect Dis 2006; 193: 741–747.
55. Buchheidt D, Hummel M, Schleiermacher D et al. Pro-
spective clinical evaluation of a LightCycler-mediated
polymerase chain reaction assay, a nested-PCR assay and
a galactomannan enzyme-linked immunosorbent assay for
detection of invasive aspergillosis in neutropenic cancer
patients and haematological stem cell transplant recipi-
ents. Br J Haematol 2004; 125: 196–202.
56. Kawazu M, Kanda Y, Nannya Y et al. Prospective com-
parison of the diagnostic potential of real-time PCR, dou-
ble-sandwich enzyme-linked immunosorbent assay for
galactomannan, and a (1–>3)-beta-D-glucan test in weekly
screening for invasive aspergillosis in patients with
hematological disorders. J Clin Microbiol 2004; 42: 2733–
2741.
57. Hebart H, Lo¨ffler J, Meisner C et al. Early detection of
aspergillus infection after allogeneic stem cell transplan-
tation by polymerase chain reaction screening. J Infect Dis
2000; 181: 1713–1719.
58. Ascioglu S. et al. Defining opportunistic invasive fungal
infections in immunocompromised patients with cancer
and hematopoietic stem cell transplants: an international
consensus. Clin Infect Dis 2002; 34: 7–14.
59. White PL, Barton R, Guiver M et al. A consensus on fungal
polymerase chain reaction diagnosis?: a United Kingdom–
Ireland evaluation of polymerase chain reaction methods
for detection of systemic fungal infections. J Mol Diagn
2006; 8: 376–384.
60. Millon L, Piarroux R, Deconinck E et al. Use of real-time
PCR to process the first galactomannan-positive serum
sample in diagnosing invasive aspergillosis. J Clin Micro-
biol 2005; 43: 5097–5101.
61. Weisser M, Rausch C, Droll A et al. Galactomannan does
not precede major signs on a pulmonary computerized
tomographic scan suggestive of invasive aspergillosis in
patients with hematological malignancies. Clin Infect Dis
2005; 41: 1143–1149.
62. Francesconi et al. Characterization and comparison of ga-
lactomannan enzyme immunoassay and quantitative real-
time PCR assay for detection of Aspergillus fumigatus in
bronchoaveolar lavage fluid from experimental invasive
pulmonary aspergillosis. J Clin Microbiol 2006; 44: 2475–
2480.
63. Martino R, Viscoli C. Empirical antifungal therapy in
patients with neutropenia and persistent or recurrent fever
of unknown origin. Br J Haematol 2006; 132: 138–154.
64. Maertens J. et al. Galactomannan and computed tomo-
graphy-based preemptive antifungal therapy in neu-
tropenic patients at high risk for invasive fungal infection:
a prospective feasibility study. Clin Infec Dis 2005; 41:
1242–1250.
65. Cordonnier C. Empirical versus pre-emptive antifungal
therapy in high-risk febrile neutropenic patients: a pro-
spective randomized study. In: Abstracts of the 48th Annual
Meeting of Hematology, 9–12 December. Orlando, Florida,
2006.
66. Hebart H et al. A prospective randomized controlled
trial comparing PCR-based and empirical treatment with
liposomal amphotericin B in patients after allogeneic
stem cell transplantation. Br J Haematol (in press).
67. Lass-Florl C. et al. Epidemiology and outcome of infections
due to Aspergillus terreus: 10 year single centre experi-
ence. Br J. Haematol 2005; 131: 201–207.
68. Lass-Florl C. et al. Molecular typing of Aspergillus terreus
isolates collected in Houston, Texas, and Innsbruck, Aus-
tria: evidence of great genetic diversity. J Clin Microbiol
2007; 45: 2686–2690.
69. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomyco-
sis in a tertiary-care cancer center in the era of Aspergillus-
active antifungal therapy: a case-control observational
study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360.
70. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology
and outcome of zygomycosis: a review of 929 reported
cases. Clin Infect Dis 2005; 41: 634–653.
71. Machouart M, Larche´ J, Burton K et al. Genetic identifi-
cation of the main opportunistic Mucorales by PCR-
restriction fragment length polymorphism. J Clin Microbiol
2006; 44: 805–810.
72. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin
inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase,
lowers burden in brain measured by quantitative PCR,
and improves survival at a low but not a high dose during
murine disseminated zygomycosis. Antimicrob Agents
Chemother 2005; 49: 721–727.
Einsele and Loeffler Contribution of new diagnostic approaches 45
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 4), 37–45
